Document is current

Article History

Received: 8 May 2017

Accepted: 8 June 2018

First Online: 18 June 2018

Authors’ information

: M.G. will coordinate the present research project as part of her PhD thesis.

: The study, including the French version of the protocol (dated June 27, 2016), has been approved by the Quebec Heart and Lung Institute Institutional Ethics Committee (MP-10-2016-2591). Any protocol amendments will be approved by the Quebec Heart and Lung Institute research ethics committee. The study coordinator (M.G.) will be responsible for communicating any of these amendments to coinvestigators and study participants.We will obtain implied informed consent from educators who participate in the satisfaction and learning assessments.Before videotaping TPE interventions, we will ask educators for written informed consent, whereas COPD patients, who will not be seen on the videos, will provide verbal informed consent.Educators will also provide written informed consent to participate in interviews.Before patient outcome assessments, we will obtain verbal informed consent from COPD patients.The consent form and other related documentation given to participants and authorized surrogates can be obtained upon request from the Quebec Heart and Lung Institute Institutional Ethics Committee at: gur@criucpq.ulaval.ca.

: We will assure confidentiality by giving all participants a unique identifier. We will remove any potentially identifiable information prior to reporting and publishing our findings. We will obtain consent to publish from the participant to report individual data.

: The authors alone are responsible for the content and writing of this paper. The Laval University Knowledge Translation, Education and Prevention Chair in Respiratory and Cardiovascular Health is supported by unrestricted grants from AstraZeneca. The Chair has received funding from GlaxoSmithKline for the development and deployment of the educational component. The program funds will not be used in connection with the research. The funding body has no role in the study design, collection, analysis or interpretation of data. The publication of our study results will not be contingent on our sponsor’s approval or censorship of the manuscript. M.G. considers having no conflict of interest, but wishes to declare what could be perceived as potential conflicts of interest. Conference (honorarium): AstraZeneca. J.M., S.L., C.H., P.C., and J.B. declare that they have no competing interests in this work. L.P.B. considers having no conflict of interest, but wishes to declare what can be perceived as potential conflicts of interest. Advisory Boards: GlaxoSmithKline, Novartis. Conferences (honoraria): AstraZeneca, GlaxoSmithKline, Merck, Novartis. Sponsorship for investigator-generated research: AstraZeneca, GlaxoSmithKline, Merck Frosst, Schering. Sponsorship for research funding for participating in multicenter studies: AllerGen, Altair, Amgen, Asmacure, AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Ono Pharma, Pharmaxis, Schering, Wyeth. Support for the production of educational materials: AstraZeneca, GlaxoSmithKline, Merck Frosst, Boehringer-Ingelheim, Novartis. Organizational: Chair of the Global Initiative for Asthma (GINA) Guidelines Dissemination and Implementation Committee, Knowledge Translation, Education and Prevention Chair in Respiratory and Cardiovascular Health, Member of the Executive Committee of Interasma (Global Asthma Organization).

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.